Skip to main content
Erschienen in: Clinical Pharmacokinetics 13/2003

01.11.2003 | Original Research Article

Forecasting of Blood Tacrolimus Concentrations Based on the Bayesian Method in Adult Patients Receiving Living-Donor Liver Transplantation

verfasst von: Masahide Fukudo, Ikuko Yano, Sachio Fukatsu, Hideyuki Saito, Shinji Uemoto, Tetsuya Kiuchi, Koichi Tanaka, Professor Ken-ichi Inui

Erschienen in: Clinical Pharmacokinetics | Ausgabe 13/2003

Einloggen, um Zugang zu erhalten

Abstract

Objective: To evaluate Bayesian prediction of blood tacrolimus concentrations in adult patients receiving living-donor liver transplantation (LDLT) using previously obtained population pharmacokinetic parameters.
Patients and methods: Data were retrospectively collected from 47 adult patients receiving LDLT who were not included in the estimation of population pharmacokinetic parameters. Blood tacrolimus concentrations were predicted without or with the empirical Bayesian method using sparse samples obtained in the previous week. Predictive performance of the concentrations was evaluated by the mean prediction error (ME), mean absolute prediction error (MAE) and root mean square error (RMSE) as well as the percentage of successful predictions (percentage of absolute prediction error less than 3 μg/L, %PRED3).
Results: Concentrations predicted by the population mean pharmacokinetic parameter values coincided well with observed concentrations during the period of tacrolimus infusion immediately after the operation. For concentrations during subsequent oral therapy with tacrolimus, predictability by the population mean pharmacokinetic parameter values alone was not satisfactory. Bayesian forecasting using one or two blood concentrations obtained in the previous week significantly decreased (p < 0.05) MAE and RMSE compared with predictions based on the population mean pharmacokinetic parameters on postoperative days 21 and 28, but not on day 14. During postoperative days 15–21, %PRED3 was increased to 68.6% or 71.2% with the Bayesian method using one or two blood concentrations, respectively, from 44.9% with the population mean pharmacokinetic parameter values.
Conclusion: The present study demonstrated the applicability of the Bayesian method with use of one or two samples for prediction of blood tacrolimus concentrations in adult patients receiving LDLT.
Literatur
1.
Zurück zum Zitat Busuttil RW, Holt CD. Tacrolimus is superior to cyclosporine in liver transplantation. Transplant Proc 1998; 30: 2174–8CrossRefPubMed Busuttil RW, Holt CD. Tacrolimus is superior to cyclosporine in liver transplantation. Transplant Proc 1998; 30: 2174–8CrossRefPubMed
2.
Zurück zum Zitat Broelsch CE, Whitington PF, Emond JC, et al. Liver transplantation in children from living related donors: surgical techniques and results. Ann Surg 1991; 214: 428–37CrossRefPubMedPubMedCentral Broelsch CE, Whitington PF, Emond JC, et al. Liver transplantation in children from living related donors: surgical techniques and results. Ann Surg 1991; 214: 428–37CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat De Ville De Goyet J, Hausleithner V, Reding R, et al. Impact of innovative techniques on the waiting list and results in pediatrie liver transplantation. Transplantation 1993; 56: 1130–6CrossRefPubMed De Ville De Goyet J, Hausleithner V, Reding R, et al. Impact of innovative techniques on the waiting list and results in pediatrie liver transplantation. Transplantation 1993; 56: 1130–6CrossRefPubMed
4.
Zurück zum Zitat Tanaka K, Uemoto S, Tokunaga Y, et al. Living related liver transplantation in children. Am J Surg 1994; 168: 41–8CrossRefPubMed Tanaka K, Uemoto S, Tokunaga Y, et al. Living related liver transplantation in children. Am J Surg 1994; 168: 41–8CrossRefPubMed
5.
Zurück zum Zitat Inomata Y, Tanaka K, Egawa H, et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation 1996; 61: 247–52CrossRefPubMed Inomata Y, Tanaka K, Egawa H, et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation 1996; 61: 247–52CrossRefPubMed
6.
Zurück zum Zitat Yasuhara M, Hashida T, Toraguchi M, et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatrie patients receiving living-related donor liver transplantations. Transplant Proc 1995; 27: 1108–10PubMed Yasuhara M, Hashida T, Toraguchi M, et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatrie patients receiving living-related donor liver transplantations. Transplant Proc 1995; 27: 1108–10PubMed
7.
Zurück zum Zitat Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404–30CrossRefPubMed Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404–30CrossRefPubMed
8.
Zurück zum Zitat Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001; 40: 283–95CrossRefPubMed Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001; 40: 283–95CrossRefPubMed
9.
Zurück zum Zitat Sam WJ, Aw M, Quak SH, et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol 2000; 50: 531–41CrossRefPubMedPubMedCentral Sam WJ, Aw M, Quak SH, et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol 2000; 50: 531–41CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat García Sánchez MJ, Manzanares C, Santos-Buelga D, et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 2001; 40: 63–71CrossRefPubMed García Sánchez MJ, Manzanares C, Santos-Buelga D, et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 2001; 40: 63–71CrossRefPubMed
11.
Zurück zum Zitat Staatz CE, Taylor PJ, Lynch SV, et al. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation 2001; 72: 1056–61CrossRefPubMed Staatz CE, Taylor PJ, Lynch SV, et al. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation 2001; 72: 1056–61CrossRefPubMed
12.
Zurück zum Zitat Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281–90CrossRefPubMed Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281–90CrossRefPubMed
13.
Zurück zum Zitat Beal SL, Boeckmann AJ, Sheiner LB. NONMEM Users Guides. San Francisco: NONMEM Project Group, University of California, 1992 Beal SL, Boeckmann AJ, Sheiner LB. NONMEM Users Guides. San Francisco: NONMEM Project Group, University of California, 1992
14.
Zurück zum Zitat Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving livingdonor liver transplantation. Eur J Clin Pharmacol 2001; 57: 479–84CrossRefPubMed Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving livingdonor liver transplantation. Eur J Clin Pharmacol 2001; 57: 479–84CrossRefPubMed
15.
Zurück zum Zitat Sheiner LB, Beal SL, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26: 294–305CrossRefPubMed Sheiner LB, Beal SL, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26: 294–305CrossRefPubMed
16.
Zurück zum Zitat Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982; 71: 1344–8CrossRefPubMed Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982; 71: 1344–8CrossRefPubMed
17.
Zurück zum Zitat Yukawa E, Higuchi S, Aoyama T. One-point feedback control method for phenytoin dosage adjustment. J Pharm Pharmacol 1991; 43: 499–503CrossRefPubMed Yukawa E, Higuchi S, Aoyama T. One-point feedback control method for phenytoin dosage adjustment. J Pharm Pharmacol 1991; 43: 499–503CrossRefPubMed
18.
Zurück zum Zitat Rodvold KA, Gentry CA, Plank GS, et al. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit 1995; 17: 239–46CrossRefPubMed Rodvold KA, Gentry CA, Plank GS, et al. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit 1995; 17: 239–46CrossRefPubMed
19.
Zurück zum Zitat Wrishko RE, Levine M, Khoo D, et al. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients. Ther Drug Monit 2000; 22: 522–31CrossRefPubMed Wrishko RE, Levine M, Khoo D, et al. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients. Ther Drug Monit 2000; 22: 522–31CrossRefPubMed
20.
Zurück zum Zitat Charpiat B, Falconi I, Bréant V, et al. A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. Ther Drug Monit 1998; 20: 158–64CrossRefPubMed Charpiat B, Falconi I, Bréant V, et al. A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. Ther Drug Monit 1998; 20: 158–64CrossRefPubMed
21.
Zurück zum Zitat Leger F, Debord J, Meur YL, et al. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. Clin Pharmacokinet 2002; 41: 71–80CrossRefPubMed Leger F, Debord J, Meur YL, et al. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. Clin Pharmacokinet 2002; 41: 71–80CrossRefPubMed
22.
Zurück zum Zitat Macchi-Andanson M, Charpiat B, Jelliffe RW, et al. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit 2001; 23: 129–33CrossRefPubMed Macchi-Andanson M, Charpiat B, Jelliffe RW, et al. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit 2001; 23: 129–33CrossRefPubMed
23.
Zurück zum Zitat Grenier FC, Luczkiw J, Bergmann M, et al. A whole blood FK506 assay for the IMx® analyzer. Transplant Proc 1991; 23: 2748–9PubMed Grenier FC, Luczkiw J, Bergmann M, et al. A whole blood FK506 assay for the IMx® analyzer. Transplant Proc 1991; 23: 2748–9PubMed
24.
Zurück zum Zitat Cogill JL, Taylor PJ, Westley IS, et al. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. Clin Chem 1998; 44: 1942–6PubMed Cogill JL, Taylor PJ, Westley IS, et al. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. Clin Chem 1998; 44: 1942–6PubMed
25.
Zurück zum Zitat Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503–12CrossRefPubMed Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503–12CrossRefPubMed
26.
Zurück zum Zitat Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111–80CrossRefPubMed Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111–80CrossRefPubMed
27.
Zurück zum Zitat Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41–9CrossRefPubMed Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41–9CrossRefPubMed
28.
Zurück zum Zitat Mathis AS, Direnzo T, Friedman GS, et al. Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. Transplantation 2001; 71: 1069–75CrossRefPubMed Mathis AS, Direnzo T, Friedman GS, et al. Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. Transplantation 2001; 71: 1069–75CrossRefPubMed
29.
Zurück zum Zitat Jones TE, Morris RG. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002; 41: 381–8CrossRefPubMed Jones TE, Morris RG. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002; 41: 381–8CrossRefPubMed
30.
Zurück zum Zitat Fitzsimmons WE, Bekersky I, Dressier D, et al. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc 1998; 30: 1359–64CrossRefPubMed Fitzsimmons WE, Bekersky I, Dressier D, et al. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc 1998; 30: 1359–64CrossRefPubMed
31.
Zurück zum Zitat Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 24–31CrossRefPubMed Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 24–31CrossRefPubMed
32.
Zurück zum Zitat Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variability in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248–60CrossRefPubMed Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variability in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248–60CrossRefPubMed
33.
Zurück zum Zitat Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40(3): 159–68CrossRefPubMed Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40(3): 159–68CrossRefPubMed
34.
Zurück zum Zitat Hashida T, Masuda S, Uemoto S, et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001; 69: 308–16CrossRefPubMed Hashida T, Masuda S, Uemoto S, et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001; 69: 308–16CrossRefPubMed
35.
Zurück zum Zitat Ds’Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9: 739–56CrossRef Ds’Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9: 739–56CrossRef
Metadaten
Titel
Forecasting of Blood Tacrolimus Concentrations Based on the Bayesian Method in Adult Patients Receiving Living-Donor Liver Transplantation
verfasst von
Masahide Fukudo
Ikuko Yano
Sachio Fukatsu
Hideyuki Saito
Shinji Uemoto
Tetsuya Kiuchi
Koichi Tanaka
Professor Ken-ichi Inui
Publikationsdatum
01.11.2003
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 13/2003
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200342130-00006

Weitere Artikel der Ausgabe 13/2003

Clinical Pharmacokinetics 13/2003 Zur Ausgabe